Novartis had changed the name of Fingolimod to Gilenia (aka FTY720).
 

They did this back in late February, when they also found out that the Food and Drug Administration (FDA) had decided to give the drug "priority review" status.

We should hear something by the end of June.

It will be interesting to see how many of us will jump on the "oral drug bandwagon" and how many will stay with our current drugs. Of course, our neurologists also have a role in our medications. :rolleyes: